PDCD1 and neoplasm: Defects in DDR pathways can promote genomic instability, increase TMB and neoantigen load, and enhance tumor immunogenicity, theoretically rendering tumors more susceptible to immune checkpoint inhibition, including PD-1/PD-L1 blockade such as toripalimab [24,41,42].